Granegis

Granegis is an oral medication containing the active ingredient granisetron, a selective 5‑HT3 receptor antagonist. It is supplied in tablet form (strength not specified) and is marketed in the European Union as a prescription product. Granegis works by blocking serotonin receptors in the central and peripheral nervous system, helping to reduce nausea and vomiting associated with chemotherapy or surgery. It belongs to the antiemetic therapeutic class.

Granegis is indicated for the prevention and treatment of nausea and vomiting in specific clinical settings, particularly when these symptoms are caused by chemotherapy or surgical interventions.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV). - Treatment of established chemotherapy‑induced nausea and vomiting. - Prevention of postoperative nausea and vomiting (PONV) after surgical procedures. - Adjunct therapy for patients receiving highly emetogenic chemotherapy regimens. - Use in combination with other antiemetics when monotherapy is insufficient. - Consideration for patients with a history of motion sickness when other triggers are present.

The safety profile of Granegis includes both common and less frequent adverse reactions, which are generally mild to moderate in intensity.

Common: - Headache - Constipation - Diarrhea - Fatigue - Dizziness

Serious: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmia - QT interval prolongation - Serotonin syndrome (rare when combined with serotonergic agents)

Before initiating Granegis, clinicians should evaluate patient history and consider specific risk factors to ensure safe use.

- Assess for known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Review cardiac history, especially prolonged QT interval or arrhythmias. - Use cautiously in patients with hepatic impairment; dose adjustment may be required. - Evaluate renal function in patients with severe renal disease. - Consider pregnancy and breastfeeding status; safety data are limited. - Monitor for signs of severe constipation or bowel obstruction. - Avoid use in patients receiving other drugs that significantly prolong QT interval.

Granegis may interact with other medications, affecting its efficacy or safety profile.

Avoid: - Concurrent use with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics). - Co‑administration with potent CYP3A4 inhibitors that could increase granisetron levels.

Use with caution: - Combination with serotonergic drugs (e.g., SSRIs, tramadol) due to risk of serotonin syndrome. - Use alongside other antiemetics that also block 5‑HT3 receptors, as additive effects may occur. - Concomitant use with drugs that affect cardiac conduction (e.g., macrolide antibiotics).